Cue Biopharma

Cue Biopharma

Yahoo Finance • 11 days ago

Premarket movers: crypto, AI stocks rise, Greenland plays soar

investing.com - U.S. stock index futures rose on Monday, as investors tracked a fresh batch of artificial intelligence-related developments and movements in oil prices ahead of the start of a new trading week. Still guessing which names t... Full story

Yahoo Finance • 12 days ago

Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

Medical researcher in gloves using a tablet ©Adobe Stock Images Cue Biopharma (NASDAQ:CUE) shares rose 41.6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in pati... Full story

Yahoo Finance • 3 months ago

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

DelveInsight Business Research LLP The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted th... Full story

Yahoo Finance • 3 months ago

Cue Biopharma to raise $50M in oversubscribed private placement

Cue Biopharma (CUE [https://seekingalpha.com/symbol/CUE]) has entered into a definitive securities purchase agreement [https://seekingalpha.com/pr/20578948-cue-biopharma-announces-50_0-million-private-placement] to raise approximately $50.... Full story

Yahoo Finance • 3 months ago

Cue Biopharma Announces $50.0 Million Private Placement

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announce... Full story

Yahoo Finance • 4 months ago

Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK

The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story

Yahoo Finance • 4 months ago

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

(RTTNews) - Tuesday's top gainers in the healthcare sector included Bluejay Diagnostics, which inked a strategic partnership with Argonaut; Picard Medical, which is advancing its next-generation Emperor Total Artificial Heart; and Cingulat... Full story

Yahoo Finance • 5 months ago

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief exec... Full story

Yahoo Finance • 5 months ago

Cue Unveils $30 Mln Private Placement, License Agreement With Ascendant; Names New CEO; Stock Up

(RTTNews) - Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company, announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement for gross proceeds of approxima... Full story

Yahoo Finance • 5 months ago

Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO

Cue Biopharma Inc. (NASDAQ:CUE) is one of the 10 Unstoppable Stocks That Could Double Your Money. Cue Biopharma Inc. (NASDAQ:CUE) is one of the unstoppable stocks that could double your money. On March 27, Cue Biopharma announced a leade... Full story

Yahoo Finance • 6 months ago

Cue Biopharma To Receive $7.5M Milestone Payment

(RTTNews) - Cue Biopharma, Inc. (CUE) announced that it will receive a $7.5 million preclinical milestone payment in May 2026 under its collaboration and license agreement with Boehringer Ingelheim. The payment follows Boehringer's select... Full story

Yahoo Finance • 6 months ago

Cue Biopharma Announces CEO Transition

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for th... Full story

Yahoo Finance • 6 months ago

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset for the treatment of autoimmune and inflamma... Full story

Yahoo Finance • 8 months ago

February 2026 ASX Penny Stocks To Watch

The Australian market is facing a cautious start to the day following the Reserve Bank's recent rate hike, with ASX 200 futures indicating a potential dip amid broader global economic concerns. In this climate of uncertainty, investors oft... Full story

Yahoo Finance • 9 months ago

Cue Biopharma Announces Proposed Public Offering

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the... Full story

Yahoo Finance • 10 months ago

After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying

(RTTNews) - U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinic... Full story

Yahoo Finance • 10 months ago

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

(RTTNews) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics Inc. (SNSE) soared 62.9% to $17.20... Full story

Yahoo Finance • last year

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the... Full story

Yahoo Finance • last year

Cue Biopharma earnings beat by $0.05, revenue topped estimates

Investing.com - Cue Biopharma (NASDAQ: CUE) reported second quarter EPS of $-0.090, $0.05 better than the analyst estimate of $-0.140. Revenue for the quarter came in at $2.95M versus the consensus estimate of $1.6M. Cue Biopharma’s sto... Full story

Yahoo Finance • last year

Cue Biopharma Inc (NASDAQ:CUE) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected

CUE BIOPHARMA INC (NASDAQ:CUE [https://www.chartmill.com/stock/quote/CUE/profile]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, NARROWER-THAN-EXPECTED LOSS Cue Biopharma Inc released its second-quarter 2025 financial results, postin... Full story